Finerenone reduces cardiovascular and kidney disease risk in type 2 diabetes
May 16, 2026
Highly relevant
Interventions:
Strength:
Diabetic Kidney Disease: Evidence-Based Treatments and Outcomes
Evidence related to diabetic kidney disease
Evidence related to diabetic kidney disease, albuminuria, kidney function, nephropathy progression, end-stage renal disease, and kidney-protective diabetes treatments.
3
Studies
6
Evidence Pairs
Experimental
Quality: 42/100
Supporting Studies
3
Research documents analyzed
Evidence Pairs
6
Intervention-outcome relationships
Latest Publication
May 2026
Avg. Evidence: 42/100
Evidence Snapshot
Qualitative overview of the evidence landscape
Moderate Confidence
Practical Questions
Does Finerenone improve albuminuria?
intervention effectivenessResearch shows Finerenone has been studied in relation to 1 different outcome with limited evidence.
Does Finerenone improve composite kidney outcomes?
intervention effectivenessResearch shows Finerenone has been studied in relation to 1 different outcome with limited evidence.
Does Dapagliflozin reduce renal and urinary disorders incidence?
intervention effectivenessResearch shows Dapagliflozin has been studied in relation to 1 different outcome with limited evidence.
Does Integrated multidisciplinary diabetes and kidney care program improve albuminuria?
intervention effectivenessResearch shows Integrated multidisciplinary diabetes and kidney care program has been studied in relation to 1 different outcome with limited evidence.
Does Finerenone improve hyperkalemia?
intervention effectivenessResearch shows Finerenone has been studied in relation to 1 different outcome with weak evidence.
Studied interventions
Interventions studied in relation to this topic
Dapagliflozin
1 study
View evidence
Finerenone
1 study
View evidence
Integrated multidisciplinary diabetes and kidney care program
1 study
View evidence
Note: Evidence strength is calculated from multiple factors including study quality, consistency, and effect sizes. Click any option to explore the supporting research in our archive.
Strongest evidence signals
Key patterns and insights identified across the research landscape
Moderate positive signal
Dapagliflozin may improve Renal and urinary disorders incidence
Dapagliflozin → Renal and urinary disorders incidence
Across 1 study, Dapagliflozin shows a moderate positive signal for Renal and urinary disorders incidence.
1 studies
Moderate positive signal
Finerenone may improve Albuminuria
Finerenone → Albuminuria
Across 1 study, Finerenone shows a moderate positive signal for Albuminuria.
1 studies
Moderate positive signal
Finerenone may improve Composite kidney outcomes
Finerenone → Composite kidney outcomes
Across 1 study, Finerenone shows a moderate positive signal for Composite kidney outcomes.
1 studies
Supporting Research
Selected studies that best represent the evidence behind this topic.
View research summary→
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
May 16, 2026
High quality
Interventions:
Strength:
Pentoxifylline may protect kidney and heart health in diabetic nephropathy
Jun 1, 2026
Recent
Interventions:
Strength:
Mediterranean ketogenic eating matched VLCKD for weight loss over 3 months
May 27, 2026
Recent
Interventions:
Outcomes:
Strength:
Wearable-supported exercise guidance may improve walking capacity in type 2 diabetes
Jun 1, 2026
Recent
Interventions:
Outcomes:
Strength:
Eating vegetables first may reduce risk of diabetic eye and kidney damage
May 16, 2026
Recent
Interventions:
Outcomes:
Strength:
Click any study to view the full research summary, or click interventions and outcomes to filter the archive.
Explore all supporting studies
Browse the complete evidence archive for this topic, including interventions, outcomes, and related research. Use powerful filters to find exactly what you're looking for.
View All Supporting StudiesFilter by study type, publication date, effect size, and more to refine your research